In this paper, we propose a multi-scene adaptive crowd counting method based on meta-knowledge and multi-task learning. In practice, surveillance cameras are stationarily deployed in various scenes. Considering the extensibility of a surveillance system, the ideal crowd counting method should have a strong generalization capability to be deployed in unknown scenes. On the other hand, given the diversity of scenes, it should also effectively suit each scene for better performance. These two objectives are contradictory, so we propose a coarse-to-fine pipeline including meta-knowledge network and multi-task learning. Specifically, at the coarse-grained stage, we propose a generic two-stream network for all existing scenes to encode meta-knowledge especially inter-frame temporal knowledge. At the fine-grained stage, the regression of the crowd density map to the overall number of people in each scene is considered a homogeneous subtask in a multi-task framework. A robust multi-task learning algorithm is applied to effectively learn scene-specific regression parameters for existing and new scenes, which further improve the accuracy of each specific scenes. Taking advantage of multi-task learning, the proposed method can be deployed to multiple new scenes without duplicated model training. Compared with two representative methods, namely AMSNet and MAML-counting, the proposed method reduces the MAE by 10.29% and 13.48%, respectively.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104539 | PMC |
http://dx.doi.org/10.3390/s22093320 | DOI Listing |
J Chem Inf Model
January 2025
School of Computer Science and Engineering, Nanjing University of Science and Technology, Nanjing 210094, China.
The accurate identification of protein-nucleotide binding residues is crucial for protein function annotation and drug discovery. Numerous computational methods have been proposed to predict these binding residues, achieving remarkable performance. However, due to the limited availability and high variability of nucleotides, predicting binding residues for diverse nucleotides remains a significant challenge.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Janssen Research & Development, A Division of Janssen Pharmaceutica, Neuroscience Therapeutic Area, Beerse, Belgium
Background: Neurodegenerative diseases are a heterogeneous group of illnesses. Differences across patients exist in the underlying biological drivers of disease. Furthermore, cross‐diagnostic disease mechanisms exist, and different pathologies often co‐occur in the brain.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Penn State University College of Medicine, Hershey, PA, USA
Background: AD prevention and early interventions require tools for evaluation of people during aging for diagnosis and prognosis of AD conversion. Since AD is a complicated continuum of neurodegenerative processes, developing of such tools have been difficult because it needs longitudinal and multimodal data which are often complicated and incomplete. To address this challenge, we are developing AI4AD framework using ADNI data.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The University of Texas Health Science Center at Houston, Houston, TX, USA
Background: Developing drugs for treating Alzheimer’s disease (AD) has been extremely challenging and costly due to limited knowledge on underlying biological mechanisms and therapeutic targets. Repurposing drugs or their combination has shown potential in accelerating drug development due to the reduced drug toxicity while targeting multiple pathologies.
Method: To address the challenge in AD drug development, we developed a multi‐task machine learning pipeline to integrate a comprehensive knowledge graph on biological/pharmacological interactions and multi‐level evidence on drug efficacy, to identify repurposable drugs and their combination candidates
Result: Using the drug embedding from the heterogeneous graph representation model, we ranked drug candidates based on evidence from post‐treatment transcriptomic patterns, mechanistic efficacy in preclinical models, population‐based treatment effect, and Phase 2/3 clinical trials.
Med Image Anal
December 2024
University Lyon, INSA Lyon, CNRS, Inserm, CREATIS UMR5220, U1206, Lyon 69621, France.
Deep learning methods have been widely used for various glioma predictions. However, they are usually task-specific, segmentation-dependent and lack of interpretable biomarkers. How to accurately predict the glioma histological grade and molecular subtypes at the same time and provide reliable imaging biomarkers is still challenging.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!